Cadrenal Therapeutics Inc CVKD

Healthcare Biotechnology

Cadrenal Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (ESRD), and atrial fibrillation (irregular heartbeat) (AFib). The Company’s lead drug candidate, tecarfarin, is an anticoagulant that uses a drug design process which targets a different pathway than the most prescribed drugs used in the treatment of thrombosis and AFib. Tecarfarin is a Phase III-ready, vitamin K antagonist (VKA), taken once a day as an oral anticoagulant like warfarin. Tecarfarin was developed using a retrometabolic drug design process which targets a different metabolic pathway from the one targeted by the most prescribed anticoagulants. Tecarfarin was designed to follow a metabolic pathway distinct from the CYP450 pathway and is metabolized by both CYP450 and non-CYP450 pathways.

NDAQ:CVKD - Post by User

Cadrenal Therapeutics Inc

<< Previous

Bullboard Posts

Next >>

Post by Iseneschalon Sep 13, 2024 11:20am

36 Views

Post# 36222302

CVKD.....My take ....FWIW

This up-coming meeting with FDA could prov to be a major catalyst

Caution is needed

This has to hold ~ $9.20 or I will say somebody knows something ...no conspiracy here

I'm sure I'm wrong

Glad I sold at the low volume pump ; )

I like to take what the market gives.....always!!!!!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario